[go: up one dir, main page]

CN113164605A - 一氧化氮合酶通路抑制剂在制备药物中的用途 - Google Patents

一氧化氮合酶通路抑制剂在制备药物中的用途 Download PDF

Info

Publication number
CN113164605A
CN113164605A CN202080005818.6A CN202080005818A CN113164605A CN 113164605 A CN113164605 A CN 113164605A CN 202080005818 A CN202080005818 A CN 202080005818A CN 113164605 A CN113164605 A CN 113164605A
Authority
CN
China
Prior art keywords
nitric oxide
oxide synthase
gastrointestinal tract
ischemia
reperfusion
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN202080005818.6A
Other languages
English (en)
Inventor
周宏伟
徐开宇
高徐璇
尹恝
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Southern Medical University Zhujiang Hospital
Original Assignee
Southern Medical University Zhujiang Hospital
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Southern Medical University Zhujiang Hospital filed Critical Southern Medical University Zhujiang Hospital
Priority to CN202410036265.0A priority Critical patent/CN117867100A/zh
Publication of CN113164605A publication Critical patent/CN113164605A/zh
Pending legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/155—Amidines (), e.g. guanidine (H2N—C(=NH)—NH2), isourea (N=C(OH)—NH2), isothiourea (—N=C(SH)—NH2)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/17—Amides, e.g. hydroxamic acids having the group >N—C(O)—N< or >N—C(S)—N<, e.g. urea, thiourea, carmustine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A61K31/573—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Wood Science & Technology (AREA)
  • Genetics & Genomics (AREA)
  • Zoology (AREA)
  • Analytical Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Biotechnology (AREA)
  • Immunology (AREA)
  • Microbiology (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Pathology (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

本申请涉及一氧化氮合酶通路抑制剂在制备药物中的用途，所述药物用于预防、缓解和/或治疗受试者中胃肠道缺血再灌注相关的远端损伤。本申请还涉及一氧化氮合酶用于筛选药物的用途，其中所述药物用于预防、缓解和/或治疗受试者中胃肠道缺血再灌注相关的远端损伤。本申请还涉及包含所述一氧化氮合酶通路抑制剂的药物组合物以及预防、缓解和/或治疗受试者中胃肠道缺血再灌注相关的远端损伤的方法。

Description

PCT国内申请，说明书已公开。

Claims (24)

  1. PCT国内申请，权利要求书已公开。
CN202080005818.6A 2019-12-12 2020-12-11 一氧化氮合酶通路抑制剂在制备药物中的用途 Pending CN113164605A (zh)

Priority Applications (1)

Application Number Priority Date Filing Date Title
CN202410036265.0A CN117867100A (zh) 2019-12-12 2020-12-11 一氧化氮合酶通路抑制剂在制备药物中的用途

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
CN2019112746631 2019-12-12
CN201911274663 2019-12-12
PCT/CN2020/135595 WO2021115412A1 (zh) 2019-12-12 2020-12-11 一氧化氮合酶通路抑制剂在制备药物中的用途

Related Child Applications (1)

Application Number Title Priority Date Filing Date
CN202410036265.0A Division CN117867100A (zh) 2019-12-12 2020-12-11 一氧化氮合酶通路抑制剂在制备药物中的用途

Publications (1)

Publication Number Publication Date
CN113164605A true CN113164605A (zh) 2021-07-23

Family

ID=76329353

Family Applications (2)

Application Number Title Priority Date Filing Date
CN202080005818.6A Pending CN113164605A (zh) 2019-12-12 2020-12-11 一氧化氮合酶通路抑制剂在制备药物中的用途
CN202410036265.0A Pending CN117867100A (zh) 2019-12-12 2020-12-11 一氧化氮合酶通路抑制剂在制备药物中的用途

Family Applications After (1)

Application Number Title Priority Date Filing Date
CN202410036265.0A Pending CN117867100A (zh) 2019-12-12 2020-12-11 一氧化氮合酶通路抑制剂在制备药物中的用途

Country Status (4)

Country Link
US (1) US20220401386A1 (zh)
EP (1) EP4074341A4 (zh)
CN (2) CN113164605A (zh)
WO (1) WO2021115412A1 (zh)

Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1207098A (zh) * 1995-11-07 1999-02-03 阿斯特拉公司 作为氧化氮合酶抑制剂的脒和异硫脲衍生物
CN102480932A (zh) * 2009-09-01 2012-05-30 阿昂梅迪克斯公司 源于肠道共生细菌的细胞外小泡及利用其的疾病模型、疫苗、备选药物筛选方法与诊断方法
CN102579510A (zh) * 2011-01-10 2012-07-18 刘振权 冬虫夏草的一种新用途
CN103405408A (zh) * 2013-06-27 2013-11-27 郝峻巍 白杨素在治疗缺血性脑卒中药物中的应用
CN104302326A (zh) * 2012-03-14 2015-01-21 利维塞普特有限公司 P75ntr神经营养因子结合蛋白的治疗性用途
CN105232499A (zh) * 2015-10-23 2016-01-13 云南中医学院 3，4-二羟基苯甲醛制备治疗或/和预防脑缺血再灌注损伤的药物的用途
CN108484431A (zh) * 2018-03-26 2018-09-04 中国药科大学 一种肉桂酰氨基酸类化合物及其用途

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5710181A (en) * 1991-12-16 1998-01-20 Washington University Inhibition of nitric oxide formation in inflammatory bowel disease
WO2001066791A1 (en) * 2000-03-10 2001-09-13 Fujisawa Pharmaceutical Co., Ltd. Method of screening inducible nitric oxide synthase activation inhibitor

Patent Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1207098A (zh) * 1995-11-07 1999-02-03 阿斯特拉公司 作为氧化氮合酶抑制剂的脒和异硫脲衍生物
CN102480932A (zh) * 2009-09-01 2012-05-30 阿昂梅迪克斯公司 源于肠道共生细菌的细胞外小泡及利用其的疾病模型、疫苗、备选药物筛选方法与诊断方法
CN102579510A (zh) * 2011-01-10 2012-07-18 刘振权 冬虫夏草的一种新用途
CN104302326A (zh) * 2012-03-14 2015-01-21 利维塞普特有限公司 P75ntr神经营养因子结合蛋白的治疗性用途
CN103405408A (zh) * 2013-06-27 2013-11-27 郝峻巍 白杨素在治疗缺血性脑卒中药物中的应用
CN105232499A (zh) * 2015-10-23 2016-01-13 云南中医学院 3，4-二羟基苯甲醛制备治疗或/和预防脑缺血再灌注损伤的药物的用途
CN108484431A (zh) * 2018-03-26 2018-09-04 中国药科大学 一种肉桂酰氨基酸类化合物及其用途

Non-Patent Citations (7)

* Cited by examiner, † Cited by third party
Title
DANIELISOVA V，等: "Aminoguanidine Administration Ameliorates Hippocampal Damage After Middle Cerebral Artery Occlusion in Rat", 《NEUROCHEMICAL RESEARCH》 *
KAIYU XU，等: "Rapid gut dysbiosis induced by stroke exacerbates brain infarction in turn", 《GUT》 *
杨英，等: ""一氧化氮合酶抑制剂对实验性大鼠结肠炎疗效的研究", 《胃肠病学》 *
胡博，等: "氨基胍对大鼠肠缺血再灌注损伤的保护作用", 《临床儿科杂志》 *
谢彩霞，等: "创伤性脑损伤患者肠屏障功能研究现状", 《护理管理杂志》 *
钟慈声，等: "《一氧化氮的生物医学》", 28 February 1997, 上海医科大学出版社 *
黄斌，等: "一氧化氮合酶及其抑制剂与脑缺血", 《国外医学神经病学神经外科学分册》 *

Also Published As

Publication number Publication date
US20220401386A1 (en) 2022-12-22
CN117867100A (zh) 2024-04-12
EP4074341A1 (en) 2022-10-19
WO2021115412A1 (zh) 2021-06-17
EP4074341A4 (en) 2024-02-28

Similar Documents

Publication Publication Date Title
Wöhrl et al. Histamine intolerance-like symptoms in healthy volunteers after oral provocation with liquid histamine.
ES2794125T3 (es) Composición farmacéutica para prevenir o tratar enfermedades metabólicas, que comprende Bacteroides acidifaciens como principio activo
KR20100045457A (ko) 알코올 소비의 증상을 감소시키는 방법
CN105517546A (zh) 治疗脆性x综合征及相关疾病的方法
JP7524167B2 (ja) Ｉｖ型コラーゲン疾患の処置のためのビフェニルスルホンアミド化合物
EP4436573A1 (en) Therapy selection and treatment of neurodegenerative disorders
EP3622952A1 (en) Agent for promoting decomposition and excretion of amyloid-
WO2022253034A1 (zh) 吡咯并嘧啶类化合物的用途
CN113768943B (zh) Tlr4通路抑制剂在制备药物中的用途
CN113164605A (zh) 一氧化氮合酶通路抑制剂在制备药物中的用途
HK40083993A (zh) 一氧化氮合酶通路抑制剂在制备药物中的用途
EP4000421B1 (en) Composition for use in ameliorating inflammatory bowel disease containing tisochrysis lutea
CN113262303B (zh) 硝酸盐还原酶抑制剂在制备药物中的用途
CN103476423A (zh) 用于治疗或预防纤维肌痛或慢性疲劳综合症的含有二胺氧化酶的组合物
Tan et al. Cardioprotective time-window of Penehyclidine hydrochloride postconditioning: A rat study
CN119421712A (zh) 用于多发性硬化和重症肌无力的治疗性酪氨酸激酶抑制剂
JP2009501795A (ja) 高尿酸血に関連する健康状態の治療及び予防のための組成物及び方法
EP4112067A1 (en) Application of manganese-type high-stability superoxide dismutase in prevention or treatment of stroke
KR102804780B1 (ko) 인지기능 장애의 치료용 조성물
EP4562184A2 (en) Therapy selection and treatment of neurodegenerative disorders
EP4556472A1 (en) Use of pyridone derivative
JP7691785B2 (ja) Ｈａｐｌｎ１を含む血管疾患の予防または治療用組成物
Miller Does lowering plasma homocysteine reduce vascular disease risk?
WO2025189104A1 (en) Treatment of cavernous angiomas with a 4-substituted piperidine derivative
WO2025114471A1 (en) Diamine oxidase (dao) for use in the treatment and/or prevention of dry eye disease

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
RJ01 Rejection of invention patent application after publication

Application publication date: 20210723

RJ01 Rejection of invention patent application after publication